



XTANDI (enzalutamide)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

Part A - Patient Patient Information

Patient information					
First Name:			Last Name:		
Insurance Carrier N	lame/Number:				
Group Number:			Client ID:		
Date of Birth (YYYY/MM/DD):			Relationship: Employee Spouse Dependent		
Language: Eng	ilish French		Gender: Male Female		
Address:					
City:		Province:		Postal Code:	
Email address:					
Telephone (home):		Telephone (cell):		Telephone (work):	
The patient is a from the educat The patient is a	tional institution confirm spouse or a dependent ditional medical informa	endent (i.e. attending ling full-time status is e over age 18. The patie	enclosed. ent has signed the auth	ull-time). A copy of the enrolment document norization section below that allows Sun Life	
Provincial Coverage	You applied for a drug that may be covered under a provincial plan. To find out if you qualify for coverage, speak to your doctor and apply to the province. Show the provincial response letter to your pharmacist when you receive it.				
Primary Coverage	Has the patient applied for reimbursement under a primary plan? Yes No N/A What is the coverage decision of the drug? Approved Denied *Attach decision letter*				





XTANDI (enzalutamide)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	Date





XTANDI (enzalutamide)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

SECTION 1 - DRUG F				
(TANDI (enzalutami	de)	New r	request Rene	ewal request*
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
	on:			
	cian's office/Private Clir	nic Private Clinic (within Ho	snital - no nublic or gov	vernment funding)
	_	_ `	opital Tio public of gov	remment randing/
Hospital (inpatient)	Hospital (outpat	cient)		
Name of the hospital or	private clinic:			
Address:				
Oits a	Dra	vinne	Doctol code:	
City:	Pro	vince:	Postal code:	
* Please submit proof	of prior coverage if avail	lahle		
* Please submit proof	of prior coverage if avai	lable		
·		lable		
ECTION 2 - ELIGIBI	LITY CRITERIA			
SECTION 2 – ELIGIBI				
ECTION 2 – ELIGIBI 1. Please indicate if the	LITY CRITERIA ne patient satisfies the b	pelow criteria:		
ECTION 2 - ELIGIBI 1. Please indicate if the Prostate Cancer - Meta	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resist	pelow criteria:	PC) in an adult, AND	
1. Please indicate if the Prostate Cancer – Meta	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrat	pelow criteria:	PC) in an adult, AND	
1. Please indicate if the Prostate Cancer – Meta For the treatment of the patient has	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrations received chemotherap	pelow criteria: tant tion-resistant prostate cancer (mCRI		ogen deprivation
For the treatment of the patient has therapy (ADT)	LITY CRITERIA ne patient satisfies the k estatic, Castration-Resist ent of metastatic castrat is received chemotherap chemotherapy-naïve and	celow criteria: tant tion-resistant prostate cancer (mCRI y containing docetaxel, OR asymptomatic or mildly symptomat		ogen deprivation
1. Please indicate if the Prostate Cancer – Meta For the treatment The patient has therapy (ADT) Prostate Cancer – Non-	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrates received chemotherape chemotherapy-naïve and	celow criteria: tant tion-resistant prostate cancer (mCRI y containing docetaxel, OR asymptomatic or mildly symptomat	tic after failure of andro	
Prostate Cancer - Meta The patient has therapy (ADT) Prostate Cancer - Non- The patient is of the treatment in the patient is of the treatment. The patient is of the treatment.	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrates received chemotherape chemotherapy-naïve and Metastatic, Castration-Rent of non-metastatic castratic castratic castratic castration-Rent of non-metastatic castratic castratic castration-Rent of non-metastatic castratic ca	tant tion-resistant prostate cancer (mCRI y containing docetaxel, OR asymptomatic or mildly symptomat	tic after failure of andro	ND
For the treatment the rostate Cancer – Meta For the treatment has therapy (ADT) Prostate Cancer – Non- For the treatment is continuous.	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrates received chemotherape chemotherapy-naïve and Metastatic, Castration-Resistent of non-metastatic castration-Resistent o	celow criteria: tant tion-resistant prostate cancer (mCRI y containing docetaxel, OR asymptomatic or mildly symptomat	tic after failure of andro nmCRPC) in an adult, Al a Prostate Specific Ant	ND
1. Please indicate if the Prostate Cancer - Meta For the treatment The patient has therapy (ADT) Prostate Cancer - Non- For the treatment is concerned to the patient has the patient	LITY CRITERIA ne patient satisfies the bestatic, Castration-Resistent of metastatic castrates received chemotherape chemotherapy-naïve and considered to be at high months or less, AND is experienced disease p	celow criteria: cant cion-resistant prostate cancer (mCRI y containing docetaxel, OR asymptomatic or mildly symptomatic esistant stration-resistant prostate cancer (r	tic after failure of andro nmCRPC) in an adult, Al a Prostate Specific Ant tomy, OR	ND igen Doubling Time





XTANDI (enzalutamide)

Prostate Cancer - Metastatic, Castration-Sensitive	
For the treatment of metastatic castration-sensitive	e prostate cancer (mCSPC) in an adult, AND
The patient has had a bilateral orchiectomy, OR	
XTANDI will be used in combination with androgen	deprivation therapy (ADT)
OR	
None of the above criteria applies.	
Relevant additional information:	
SECTION 3 - PRESCRIBER INFORMATION	
Physician's Name:	
Address:	
Tol	Four
Tel:	Fax:
License No.:	Specialty:
Dhyeician Signaturo	Dato

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





XTANDI (enzalutamide)

SECTION 5 - CONTACT US

	You can submit all pages of this form through the mysunlife mobile app or mysunlife.ca. Please use 'prior auth' as the reference number.
--	---

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ${\mathbb R}$

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 2010 STN Waterloo Waterloo, ON N2J 0A6